Related references
Note: Only part of the references are listed.Low muscle mass is associated with early termination of chemotherapy related to toxicity in patients with head and neck cancer
Martine J. Sealy et al.
CLINICAL NUTRITION (2020)
Low skeletal muscle mass is a strong predictive factor for surgical complications and a prognostic factor in oral cancer patients undergoing mandibular reconstruction with a free fibula flap
E. Ansari et al.
ORAL ONCOLOGY (2020)
Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma
N. Chargi et al.
ORAL ONCOLOGY (2020)
Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients
Sophie Kurk et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2019)
Agreement between skeletal muscle mass measurements using computed tomography imaging and magnetic resonance imaging in head and neck cancer patients
N. Chargi et al.
ORAL ONCOLOGY (2019)
Sarcopenia: looking to muscle mass to better manage pancreatic cancer patients
Debora Basile et al.
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE (2019)
Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?
Marc Hilmi et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy
Willemieke P. M. Dijksterhuis et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2019)
Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review
Frederic Pamoukdjian et al.
CLINICAL NUTRITION (2018)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2018)
Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer
Anne W. Wendrich et al.
ORAL ONCOLOGY (2017)
A review of body composition and pharmacokinetics in oncology
Jessica J. Hopkins et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer
Jessie A. Elliott et al.
ANNALS OF SURGERY (2017)
Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients
Justin E. Swartz et al.
ORAL ONCOLOGY (2016)
Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens
Raafi Ali et al.
CANCER MEDICINE (2016)
Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer
Bjorg Sjoblom et al.
LUNG CANCER (2015)
Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation
Laura Astolfi et al.
ONCOLOGY REPORTS (2013)
Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres
M. Pressoir et al.
BRITISH JOURNAL OF CANCER (2010)
A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care
Marina Mourtzakis et al.
APPLIED PHYSIOLOGY NUTRITION AND METABOLISM (2008)
Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study
Carla M. M. Prado et al.
LANCET ONCOLOGY (2008)
Body surface area as a determinant of pharmacokinetics and drug dosing
M Sawyer et al.
INVESTIGATIONAL NEW DRUGS (2001)
Sarcopenia
JE Morley et al.
JOURNAL OF LABORATORY AND CLINICAL MEDICINE (2001)